Engineered Endolysin Platforms for Precision Control of Clostridium perfringens
Engineered bacteriophage enzymes specifically target Clostridium perfringens by breaking its cell wall. They are produced in bacterial, plant, and yeast systems, with enhanced heat stability, offering a precise and resilient alternative to antibiotics for animal feed and food safety applications.
Background
The field of microbial control in food-animal production has grown increasingly urgent as concerns mount over antibiotic resistance and the rising incidence of bacterial infections such as necrotic enteritis in poultry. Traditional reliance on broad-spectrum antibiotics has been curtailed by regulatory bans and growing awareness of their impact on human health and the environment. This shift has driven the search for alternative methods to address foodborne pathogens, with a strong need for strategies that offer precise targeting without compromising beneficial microbial communities.
Current approaches, however, face significant challenges. Many of the available antimicrobial solutions lack the specificity required to combat harmful bacteria without disrupting the overall microbiome, often leading to undesirable side effects. Additionally, several emerging alternatives are hampered by issues of stability and efficacy under the harsh conditions of feed processing and the animal gastrointestinal tract. These limitations not only reduce their practical utility in real-world applications but also raise concerns about their long-term effectiveness in mitigating the risk of persistent or recurring infections.
Technology
The technology employs engineered bacteriophage proteins that target the cell wall of Clostridium perfringens, a significant pathogen in poultry and food safety. These proteins feature specialized catalytic domains that dismantle the bacterial cell wall, causing rapid cell death. They are produced using various expression systems—including bacterial, yeast, and plant-based methods—to allow cost-effective and scalable production. An added chimeric variant retains its activity at elevated temperatures, making it suitable for applications like feed processing and the gastrointestinal environment.
This approach stands out due to its high specificity and versatility. Unlike broad-spectrum antibiotics, these proteins exclusively target Clostridium perfringens, sparing beneficial microorganisms and reducing the risk of resistance. The ability to manufacture them through different platforms ensures adaptability for varied applications, from animal feed enhancements to food safety measures. Additionally, the enhanced thermostability of the chimeric variant provides a practical solution for environments where heat stability is critical.
Benefits
- High specificity: Targets Clostridium perfringens while sparing beneficial microbiota.
- Versatile production: Efficient expression in E. coli, plants, and yeast for scalable manufacturing.
- Enhanced thermostability: Retains activity under high-temperature conditions typical of feed processing and the chicken gastrointestinal tract.
- Demonstrated efficacy: Significant reduction in C. perfringens load in both in vitro assays and ex vivo tests.
- Antibiotic alternative: Provides a targeted approach to controlling infections, supporting reduced reliance on traditional antibiotics.
Applications
- Poultry feed additive
- Food safety antimicrobial
- Veterinary therapeutic agent
Additional info
Engineered bacteriophage-derived endolysins exhibit potent lytic activity against Clostridium perfringens. Genes optimized for expression in E. coli, yeast, and plant systems incorporate glycosyl hydrolase and L-alanine amidase catalytic domains for high specificity. A chimeric, thermostable variant maintains activity during high-temperature feed processing. Functional assays—including spot lysis, turbidity reduction, and MIC tests—validate efficacy, highlighting their potential as targeted antimicrobials in food safety and animal health applications.